Southeast Asia health tech funding rebounds to $108m in H1

Deal activity doubled to 16.

Health tech startups in Southeast Asia raised $108m in the first half of the year after two consecutive semesters of correction, according to a DealstreetAsia report.

Deal activity doubled to 16 in the period. The largest transaction was Singapore-based Nuevocor’s $45m series B round to advance gene therapy for inherited cardiac diseases.

“The rebound was driven primarily by startups in curative and diagnostic technologies, which continue to capture strong investor interest given their potential for high clinical impact and defensible IP,” the report said.

In contrast, telemedicine platforms have lost traction in the post-COVID environment as patients returned to in-person care.

Expanded insurance coverage under universal healthcare policies has increased access to hospitals and clinics, contributing to the shift.